Lymphangioleiomyomatosis screening in women with tuberous sclerosis.
about
Rapamycin and its analogues (rapalogs) for tuberous sclerosis complexRapamycin and rapalogs for tuberous sclerosis complexLymphangioleiomyomatosis: differential diagnosis and optimal managementManagement of lymphangioleiomyomatosisClinical features, epidemiology, and therapy of lymphangioleiomyomatosisTuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference[Tuberous sclerosis complex].Diffuse Cystic Lung Disease. Part I.Natural history of angiomyolipoma in lymphangioleiomyomatosis: implications for screening and surveillance.TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex.Women with TSC: Relationship between Clinical, Lung Function and Radiological Features in a Genotyped Population Investigated for Lymphangioleiomyomatosis.Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis.Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development.Coexistence of pulmonary lymphangioleiomyomatosis and pulmonary angiomyolipoma.TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patientsGenomic rearrangements in sporadic lymphangioleiomyomatosis: an evolving genetic story.Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM)Imaging Manifestations of a Subependymal Giant Cell Astrocytoma in Tuberous SclerosisPharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference.EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.Tuberous sclerosis complex: the past and the future.Lymphangioleiomyomatosis: New Treatment Perspectives.Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.Tuberous sclerosis complex: Recent advances in manifestations and therapy.The economic burden of tuberous sclerosis complex in the UK: A retrospective cohort study in the Clinical Practice Research Datalink.Inactivation of Tsc2 in Mesoderm-Derived Cells Causes Polycystic Kidney Lesions and Impairs Lung Alveolarization.Cystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function.Sclerotic bone lesions as a potential imaging biomarker for the diagnosis of tuberous sclerosis complex.TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.Maternal Genetic Disorders in Pregnancy.Apparent Sporadic Lymphangioleiomyomatosis in a Man as a Result of Extreme Mosaicism for a TSC2 Mutation.Lymphangioleiomyomatosis: a case report and review of diagnosis and treatment
P2860
Q24194140-B61A1195-819E-47BD-A73B-272E24B107B9Q26471128-4CE6F2AE-C679-45BD-909A-01BD3C18FE88Q27022412-252681F4-71E9-47D2-9FFE-C8D8FDB2C480Q28084725-076E8537-1EA5-4942-8C30-D305DAF27D3BQ28084975-7B89F36A-A534-407A-8536-FEF70CCCDD70Q28298922-DD690C06-CBD3-460C-8C56-22322114C730Q30701394-410E8A89-CF3D-4F9D-8578-DE8B7E376E80Q33722950-8FA6F9F9-3A0A-4064-8761-E20FA309F273Q34374868-45A276EF-5846-43D6-A407-805B17DAC929Q34636117-EFA42075-B076-4A60-BE64-CAC0D7A2226DQ36015287-2A25D370-8F7A-494E-A9D5-E89F403903DAQ36049513-681BBFBF-C2CB-4CFE-96B9-8E6191E9A7DEQ36095750-A5F216FD-780C-45DC-B0C5-E14EE7276C5EQ36104539-6FAC954F-4438-4622-82F8-B9F014927086Q36241426-0EC93776-FCF7-4BB5-8E70-FD3E87B19ACDQ36413204-508FF860-5C26-462B-9699-76B725F3127AQ36462100-55F8D808-C760-4289-ADAD-4EF103155EA6Q36578341-E6331C70-1E05-4075-B38E-32C5D97294A4Q36806587-46191A88-7A22-450D-AB65-1CFB2FC866E8Q37038637-9023F651-3D70-4C86-8CF3-E80ADAC5A650Q37397803-68CCDC09-FE90-47C9-9A15-2B9180F9110CQ38297624-9143C528-9D60-4269-9EDE-38D014959267Q38484497-09236890-EBF2-4D4F-85F1-98BA152E0EC9Q38895095-67307634-858D-4168-B5A4-6A25858E953CQ39408346-C0D29EDC-10F1-4285-9AFE-B4808211428BQ39706758-6DC85CC2-80D1-49BB-BC75-BBF448663C2CQ46117088-955B6768-14FF-42BC-84AE-F59B2958758EQ47370738-C1AF4DB4-ED3E-458A-B846-42CD216CC4F0Q48223051-47E6C578-62DE-4E9A-9B5A-3723E2566DB1Q52316792-E1AFFBA9-CB18-4AE9-80A5-2F3CD195F508Q55245792-925DAA8C-C1B7-46FA-AC03-2723BB422960Q55624461-52AEC565-EC8F-47FB-84A7-0761B3F3740CQ58781236-12E1EBA0-04EB-4C27-A7CF-CDD582860915
P2860
Lymphangioleiomyomatosis screening in women with tuberous sclerosis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Lymphangioleiomyomatosis screening in women with tuberous sclerosis.
@en
type
label
Lymphangioleiomyomatosis screening in women with tuberous sclerosis.
@en
prefLabel
Lymphangioleiomyomatosis screening in women with tuberous sclerosis.
@en
P2093
P356
P1433
P1476
Lymphangioleiomyomatosis screening in women with tuberous sclerosis
@en
P2093
Alan S Brody
Corey J Cudzilo
Darcy A Krueger
David N Franz
Lisa R Young
Mantosh S Rattan
Rhonda D Szczesniak
P304
P356
10.1378/CHEST.12-2813
P407
P577
2013-08-01T00:00:00Z